# Bodyport

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/bodyport

- Industry: Healthcare
- Headquarters: San Francisco, US
- Website: www.bodyport.com
- Total disclosed funding: $16M
- Latest round: Series A (Aug 11, 2020)
- Investors on record: 6

## About

Bodyport Inc. is an innovative company focused on health management technology, specializing in noninvasive cardiovascular monitoring through its advanced Bodyport Cardiac Scale, enhancing patient outcomes in chronic heart conditions.Founded in 2014, Bodyport Inc. is headquartered in San Francisco, US. The company operates within the health tech sector, creating solutions for chronic heart condition management. The founders, Corey Centen and Sarah Smith, aim to leverage technology for better health outcomes. Bodyport has raised a total of USD 11.2 mn across various funding deals, with the latest round being Series A, led by Boehringer Ingelheim Venture on August 11, 2020, with participation from Initialized Capital and Playground Global, LLC.Bodyport offers a fluid management platform centered around its flagship Bodyport Cardiac Scale, which detects hemodynamic signals through users' feet. This device provides noninvasive heart function assessments and fluid status evaluations. The integrated platform includes a clinical dashboard that enhances user experience, targeting chronic heart condition patients and healthcare providers for at-home monitoring and timely interventions. Bodyport's products are primarily marketed within the US and select international markets, leveraging innovative technology to improve chronic condition management.Bodyport generates revenue through direct-to-consumer sales and partnerships with healthcare providers, primarily involving subscription models for access to its clinical dashboard and data analytics. The company collaborates with hospitals and health systems to integrate its solutions into patient care frameworks, enhancing chronic heart condition management. Specific pricing plans remain undisclosed, reflecting the tailored nature of their services to meet healthcare partners' and patients' needs.In the wake of its Series A funding of USD 11.2 mn in August 2020, Bodyport aims to expand its product offerings and market reach. The company is designing new products to enhance its platform and plans to expand into additional geographic regions by 2022. The funding will support these initiatives, allowing Bodyport to strengthen its position in the biomarker-guided digital therapeutics market, ultimately improving health outcomes for patients with chronic heart conditions.

## Funding rounds

- Series A, Aug 11, 2020, $11M — Boehringer Ingelheim Venture, Initialized Capital, Playground Global, LLC
- Seed, Feb 1, 2018, $2M — Initialized Capital
- Seed, Feb 1, 2016, $2.5M — Y Combinator, Rock Health, Playground Global, LLC
- Seed, Aug 18, 2015, $0.1M — Y Combinator, SGH Capital

## Investors

- Y Combinator (https://capitalatlas.ai/funds/y-combinator) — Seed
- SGH Capital (https://capitalatlas.ai/funds/sgh-capital) — Seed
- Rock Health (https://capitalatlas.ai/funds/rock-health) — Seed
- Playground Global, LLC — Seed, Series A
- Initialized Capital (https://capitalatlas.ai/funds/initialized-capital) — Seed, Series A
- Boehringer Ingelheim Venture (https://capitalatlas.ai/funds/boehringer-ingelheim-venture) — Series A